AKT1 and melanoma: Resistance to BRAF inhibitors (dabrafenib or vemurafenib) results from BRAF amplification, AKT mutation, N-RAS mutation, MEK1/MEK2 mutation, and high level of insulin like growth factor-1 receptor (IGF-1R) in BRAFV600E mutant melanomas (Rizos et al., 2014, Figure 1E).